Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients-Reference-Cited by-同舟云学术

Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients

Published:2014-06-15 Issue:6 Volume:32 Page:1213-1225
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Gopal Ajay K.,Tarantolo Stefano R.,Bellam Naresh,Green Damian J.,Griffin Melissa,Feldman Tatyana,Mato Anthony R.,Eisenfeld Amy J.,Stromatt Scott C.,Goy Andre

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-014-0125-2.pdf

Reference39 articles.

1. Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D, Josten KM, Durk H, Rost A, Neise M, von Grunhagen U, Chow KU, Hansmann ML, Hoelzer D, Mitrou PS (2005) Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 23(15):3383–3389. doi: 10.1200/JCO.2005.08.100

2. Robinson KS, Williams ME, van der Jagt RH, Cohen P, Herst JA, Tulpule A, Schwartzberg LS, Lemieux B, Cheson BD (2008) Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26(27):4473–4479. doi: 10.1200/JCO.2008.17.0001

3. Fowler NH, Advani RH, Sharman JP, Smith SM, McGreivy J, Kunkel L, Troung V, Zhou C, Boyd TE (2013) The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Is Active and Tolerated in Relapsed Follicular Lymphoma American Society of Hematology Annual Meeting; December 7–10, 2013; New Orleans, LA

4. Witzig TE (2005) Current treatment approaches for mantle-cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 23(26):6409–6414. doi: 10.1200/JCO.2005.55.017

5. Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G, Kaplan H, Voralia M, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Vose JM (2009) Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin’s Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27(32):5404–5409. doi: 10.1200/JCO.2008.21.1169

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Using adjusted local assortativity with Molecular Pixelation unveils colocalization of membrane proteins with immunological significance;Frontiers in Immunology;2024-06-25

2. PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine;2023-11-16

3. Theranostics of Hematologic Disorders;Nuclear Medicine and Immunology;2021-11-25

4. Advances in targeted therapy for malignant lymphoma;Signal Transduction and Targeted Therapy;2020-03-06

5. In-depth site-specific O-Glycosylation analysis of therapeutic Fc-fusion protein by electron-transfer/higher-energy collisional dissociation mass spectrometry;Biologicals;2019-03